Latvia is currently experiencing a surge in respiratory syncytial virus (RSV) cases, particularly affecting infants who face significant health risks due to this infection. Healthcare professionals express concern over the potential long-term health implications for these young patients. A notable fact highlighted is that some countries provide free antibodies for infants, placing pressure on the Latvian government to consider similar preventive measures that could safeguard vulnerable populations like newborns.

One case is that of little Marija, a two-month-old baby who has been hospitalized for five days due to RSV. Her mother, Olga, shared her experience of this challenging time, recounting the anxiety of monitoring her daughter's oxygen levels while being attached to a monitor in the hospital. This scenario underscores the pressing need for public awareness regarding RSV's dangers, especially as older siblings in the family have also contracted the virus but managed it more lightly.

Currently, the Latvian health system offers a vaccine for pregnant women, which is a proactive measure, but it is not widely known among all medical professionals. The Ministry of Health is contemplating funding for the antibody treatments, which could provide crucial support to families affected by RSV. With rising case numbers, this situation emphasizes the urgency for both awareness and action from the government to protect the health of Latvian infants from this viral infection.